Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: Results of a pooled analysis

Current Medical Research and Opinion

Volumn 28, Issue 9, 2012, Pages 1421-1433

  Feldman, R D ^a   Flack, J ^b   Howes, L ^c   Jenssen, T ^d   Reeves, R ^e   Shi, H ^f   Westergaard, M ^f   Hobbs, F D R ^g  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WAYNE STATE UNIVERSITY   (United States)

^c GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^d UNIVERSITY OF OSLO   (Norway)

^e Cardiovascular Associates PC   (United States)

^f PFIZER INC   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Age; Cardiovascular disease prevention; Cholesterol; Clinical trials; Elderly; Hypertension; Lipid lowering

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY; KIDNEY FUNCTION TEST; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SEX FACTORS; YOUNG ADULT;

EID: 84866694258     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.713339     Document Type: Article

References (39)

1. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
2. Kung HC, Hoyert DL, Xu J, et al. Deaths: final data for 2005. Natl Vital Stat Rep 2008;56:1-120
3. Viikari J, Ronnemaa T, Seppanen A, et al. Serum lipids and lipoproteins in children, adolescents and young adults in 1980-1986. Ann Med 1991;23:53-9
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
5. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
6. Jackson R, Chambless L, Higgins M, et al. Sex difference in ischaemic heart disease mortality and risk factors in 46 communities: an ecologic analysis. Cardiovasc Risk Factors 1997;7:43-54
7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
8. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ (Clinical Research edn) 2008;336:1121-3
9. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-64
10. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64
11. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
12. Collier DJ, Poulter NR, Dahlof B, et al. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens 2011;29:583-91
13. Collier DJ, Poulter NR, Dahlof B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens 2011;29:592-9
14. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291:1864-70
15. McDonald M, Hertz RP, Unger AN, et al. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 2009;64:256-63
16. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
17. Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007;5:52-63
18. Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005;7:264-73
19. Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc 2008;83:35-45
20. Erdine S, Ro YM, Tse HF, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens 2009;23: 196-210
21. Hobbs F, Gensini G, Feldman R, et al. An international open-label program to assess the efficacy of single-pill amlodipine/atorvastatin in attaining recommended BP and lipid levels: The JEWEL Programme. Eur J Cardiovasc Prev Rehabil 2009;16:472-80
22. Joint National Committee on prevention detection evaluation and treatment of high blood pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
24. Kloner RA, Sowers JR, DiBona GF, et al. Sex-and age-related antihyperten-sive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 1996;77:713-22
25. Abad-Santos F, Novalbos J, Galvez-Mugica MA, et al. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res 2005;51:445-52
26. White WB, Johnson MF, Black HR, et al. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. Am J Hypertens 2001;14:1239-47
27. Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmaco-dynamics in relation to disposition. Clin Pharmacol Ther 1990;48:76-86
28. Caduet (amlodipine besylate/atorvastatin calcium) tablets. Pfizer Labs, 2012. Available at: http://www.pfizer.com/files/products/uspi-caduet.pdf [Last accessed 9 January 2012]
29. Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992;19:508-19
30. Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension 2007;49:792-8
31. Mancia G, Parati G, Revera M, et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ (Clinical Research edn) 2010;340:c1197
32. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged565 versus 4or¼65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol 2009;103:577-82
33. Gibson DM, Bron NJ, Richens A, et al. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996; 36:242-6
34. Piepho RW, Fendler KJ. Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations. Drugs Aging 1991;1:194-211
35. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001;158:183-93
36. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorva-statin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
37. Juel K, Christensen K. Are men seeking medical advice too late? Contacts to general practitioners and hospital admissions in Denmark 2005. J Public Health (Oxf) 2008;30:111-3
38. Neutel JM, Bestermann WH, Dyess EM, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) 2009;11:22-30
39. Grimm RH, Malik M, Yunis C, et al. Early simultaneous treatment to attain blood pressure and lipid goals using amlodipine/atorvastatin single-pill therapy in a randomized controlled trial. Vasc Health Risk Manag 2010;6:261-71